Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05152147
Title A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers (HERIZON-GEA-01)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Zymeworks Inc.

gastroesophageal adenocarcinoma

gastric adenocarcinoma

esophagus adenocarcinoma

gastroesophageal junction adenocarcinoma


Capecitabine + Oxaliplatin + Trastuzumab

Capecitabine + Oxaliplatin + ZW25

Cisplatin + Fluorouracil + Trastuzumab

Cisplatin + Fluorouracil + ZW25

Cisplatin + Fluorouracil + Tislelizumab + ZW25

Capecitabine + Oxaliplatin + Tislelizumab + ZW25

Age Groups: adult | senior
Covered Countries ITA | FRA | ESP | DEU | CAN | BEL

No variant requirements are available.